Cambridge Epigenetix raises $21m series-B
Cambridge Epigenetix (CEGX), which develops epigenetic sequencing technology, has raised a $21m series-B led by GV, formerly known as Google Ventures.
Other participants were Sequoia Capital and previous backers New Science Ventures, Syncona Partners and Cambridge University.
Following the capital injection, GV general partner Tom Hulme will join CEGX's board of directors. The company also appointed a new CEO, Geoff Smith. He joins from Illumina, a company that does research on DNA, where he was vice-president of product development.
Company
CEGX is a life sciences company spun out from the University of Cambridge in 2012. It is focused on developing methods and technologies in the fields of epigenetics and personalised medicine.
People
CEGX – Geoff Smith (CEO).
GV – Tom Hulme (general partner).
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Czech Republic-headquartered family office is targeting DACH and CEE region deals
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Estonia-registered VC could bolster LP base with fresh capital from funds-of-funds or pension funds









